Citius Pharmaceuticals (CTXR) FCF Margin (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly FCF Margin came in at 581.82% in Q2 2026, down 646.19% quarter-over-quarter from 77.97% in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) FCF Margin (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported FCF Margin for 2 consecutive years, with 581.82% the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Johnson & Johnson	641.31 Bn	620.55 Bn	17.26 Bn	28.82%
2	AbbVie	445.49 Bn	438.92 Bn	12.70 Bn	18.33%
3	Merck	357.41 Bn	350.27 Bn	12.21 Bn	26.96%
4	Novartis Ag	267.66 Bn	259.97 Bn	11.24 Bn	43.05%
5	Pfizer	156.81 Bn	145.11 Bn	10.94 Bn	2.01%
6	Sanofi	52.17 Bn	44.78 Bn	10.79 Bn	25.52%
7	Revolution Medicines	42.94 Bn	42.94 Bn	-	-
8	Incyte	24.61 Bn	20.07 Bn	1.57 Bn	29.58%
9	United Therapeutics	21.31 Bn	18.64 Bn	683.80 Mn	26.25%
10	Citius Pharmaceuticals	15.70 Mn	15.70 Mn	1.00 Mn	-581.82%

Historic Data

Download Data